USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: SANARIA, INC.
City: ROCKVILLE
State: MD
Zip+4: 20850
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: http://www.sanaria.com
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $9,388,438.00 16
SBIR Phase II $24,884,447.00 9

Award List:

Attenuated Malaria Sporozoite Vaccine

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Stephen L. Hoffman
Award Amount: $543,801.00
Abstract:
DESCRIPTION (provided by applicant): Malaria causes an estimated 500 million clinical cases and up to 2.7 million deaths annually, is responsible for a loss of greater than 1% of GDP in Africa annually, and is a serious concern for travelers and military personnel. Sanaria's long term goal is to… More

Aseptic, purified attenuated sporozoite malaria vaccine

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Stephen L. Hoffman
Award Amount: $600,000.00
Abstract:
DESCRIPTION (provided by applicant): Malaria causes an estimated 500 million clinical cases and up to 2.7 million deaths annually, is responsible for a loss of greater than 1% of GDP in Africa annually, and is a serious concern for travelers and military personnel. Sanaria's goal is to develop and… More

Potency of cryopreserved, irradiated sporozoite vaccine

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Stephen L. Hoffman
Award Amount: $596,369.00
Abstract:
DESCRIPTION (provided by applicant): Malaria causes an estimated 500 million clinical cases and up to 2.7 million deaths annually, is responsible for a loss of greater than 1% of GDP in Africa annually, and is a serious concern for travelers and military personnel. Sanada's goal is to develop and… More

Attenuated Sporozoite Malaria Vaccine

Award Year / Program / Phase: 2005 / SBIR / Phase II
Agency: HHS
Principal Investigator: Stephen L. Hoffman
Award Amount: $2,999,916.00
Abstract:
DESCRIPTION (provided by applicant): Malaria causes an estimated 500 million clinical cases and up to 2.7 million deaths annually, is responsible for a loss of greater than 1% of GDP in Africa annually, and is a serious concern for travelers and military personnel.… More

Universal Attenuated Sporozoite Vaccine and Challenge System

Award Year / Program / Phase: 2006 / SBIR / Phase II
Agency: HHS
Principal Investigator: Stephen L. Hoffman
Award Amount: $2,971,676.00
Abstract:
DESCRIPTION (provided by applicant): / Abstract Malaria causes 500 million clinical cases & 1-3 million deaths/yr, is responsible for > 1% loss of GDP in Africa/yr, and is a serious concern for travelers. When attenuated P. falciparum sporozoites (PfSPZ) are administered by bite of infected… More

Lyophilization of Plasmodium falciparum sporozoite vaccine

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: HHS
Principal Investigator: Stephen L. Hoffman
Award Amount: $500,464.00
Abstract:
DESCRIPTION (provided by applicant): Malaria causes 500 million clinical cases and 1-3 million deaths annually, is responsible for a loss of > 1% of GDP in Africa annually, and is a serious concern for travelers and military personnel. When attenuated Plasmodium falciparum sporozoites (PfSPZ) are… More

Genetically Attenuated Malaria Sporozote Vaccine

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Stephen L. Hoffman
Award Amount: $598,335.00
Abstract:
DESCRIPTION (provided by applicant): Malaria causes an estimated 500 million clinical cases, up to 2.7 million deaths, and a loss of gt 1% of GDP in Africa annually, and poses a serious concern for travelers and military. Sanaria's goal is to develop and c ommercialize a gt90% protective attenuated… More

IMPROVING MANUFACTURING AND POTENCY OF CRYOPRESERVED MALARIA SPOROZOITE VACCINE

Award Year / Program / Phase: 2008 / SBIR / Phase II
Agency: HHS
Principal Investigator: Stephen L. Hoffman
Award Amount: $2,993,307.00
Abstract:
DESCRIPTION (provided by applicant): Malaria causes 500 million clinical cases and gt 1 million deaths annually, is responsible for a loss of gt 1.3% of GDP in Africa annually, and is a serious concern for travelers and the military. A vaccine would be the ideal preventive and is perhaps the only… More

Improving Production of Attenuated Malaria Sporozoite Vaccines through Genetic Mo

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $600,000.00
Abstract:
DESCRIPTION (provided by applicant): Malaria causes an estimated 500 million clinical cases and up to 2.7 million deaths per annum, reduces the GDP of Africa by gt1% and is a serious risk for travelers including military personnel. Sanaria's goal is to de velop and commercialize a gt90% protective… More

Automated Salivary Gland Dissection for Manufacture of Malaria PfSPZ Vaccine

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Stephen L. Hoffman
Award Amount: $599,616.00
Abstract:
DESCRIPTION (provided by applicant): Sanaria was founded in 2003 to develop and commercialize an attenuated sporozoite Plasmodium falciparum (Pf) (PfSPZ) vaccine against malaria. Since then Sanaria has established a manufacturing process, manufactured the PfSPZ Vaccine under cGMPs, submitted an… More

Sanaria PfSPZ Vaccine Functional T Cell Assay-Hepatocyte Cytotoxicity Assay

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Sumana Chakravarty
Award Amount: $599,012.00
Abstract:
DESCRIPTION (provided by applicant): The attenuated PfSPZ vaccine being developed by Sanaria is designed to evoke a robust adaptive immune response that will prevent mosquito transmitted sporozoites from establishing clinical malaria in vaccinated individu als. Based on decades of studies with live… More

Cryopreservation of Anopheles stephensi embryos

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Peter F. Billingsley
Award Amount: $599,957.00
Abstract:
DESCRIPTION (provided by applicant): Malaria is responsible for several hundred million cases and over one million deaths per year. A highly effective vaccine that prevents blood stage infection and thereby prevents all disease and transmission would be an ideal tool for eliminating Plasmodium… More

Lyophilization of P. falciparum Transgenic for Trehalose Synthesis/Transport

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Stephen L. Hoffman
Award Amount: $584,739.00
Abstract:
DESCRIPTION (provided by applicant): The recent call for elimination of malaria caused by Plasmodium falciparum (Pf) and eventual eradication of all malaria has focused attention on this disease, which is responsible for hundreds of millions of cases and a million deaths annually. An ideal tool for… More

Genetically Attenuated Malaria Attenuated Whole Parasite Sporozoite Vaccine

Award Year / Program / Phase: 2010 / SBIR / Phase II
Agency: HHS
Principal Investigator: Stephen L. Hoffman
Award Amount: $2,980,647.00
Abstract:
DESCRIPTION (provided by applicant): Malaria is responsible for hundreds of millions of cases and a million deaths annually. An ideal tool for eliminating Plasmodium falciparum (Pf), the causative agent of 99% of all malaria deaths, would be a highly effec tive vaccine that prevents blood stage… More

In-vitro culture of Plasmodium falciparum sporozoites for malaria vaccine

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Stephen L. Hoffman
Award Amount: $569,920.00
Abstract:
DESCRIPTION (provided by applicant): The recent call for elimination of malaria caused by Plasmodium falciparum (Pf) and eventual eradication of all malaria has focused attention on this disease, which is responsible for hundreds of millions of cases and a million deaths annually. An ideal tool for… More

Attenuated Sporozoite Malaria Vaccine

Award Year / Program / Phase: 2011 / SBIR / Phase II
Agency: HHS
Principal Investigator: Stephen L. Hoffman – 301-770-3222
Award Amount: $983,532.00
Abstract:
DESCRIPTION (provided by applicant): The recent call for elimination of malaria caused by Plasmodium falciparum and eventual eradication of all malaria has focused attention on this disease, which is responsible for hundreds of millions of cases and a million deaths annually. An ideal tool for… More

Increasing potency of attenuated sporozoite vaccines with a glycolipid adjuvant

Award Year / Program / Phase: 2011 / SBIR / Phase I
Agency: HHS
Principal Investigator: Stephen L. Hoffman – 301-770-3222
Award Amount: $598,622.00
Abstract:
DESCRIPTION (provided by applicant): There are gt300 million cases and ~1 million deaths p.a. caused by Plasmodium falciparum (Pf) malaria. Control using bednets, insecticides, and drugs, has been significant but as stressed recently in The Lancet editorial, a malaria vaccine is needed. The ideal… More

Universal Attenuated Sporozoite Vaccine and Challenge System

Award Year / Program / Phase: 2012 / SBIR / Phase II
Agency: HHS
Principal Investigator: Stephen L. Hoffman – 301-770-3222
Award Amount: $3,000,000.00
Abstract:
DESCRIPTION (provided by applicant): The ideal tool for eliminating Plasmodium falciparum (Pf), the causative agent of 99% of all malaria deaths, will be a highly effective vaccine that prevents blood stage infection and thereby prevents all disease and transmission. Sanaria's goal is to… More

IMPROVING MANUFACTURING AND POTENCY OF CRYOPRESERVED MALARIA SPOROZOITE VACCINE

Award Year / Program / Phase: 2012 / SBIR / Phase II
Agency: HHS
Principal Investigator: Stephen L. Hoffman – 301-770-3222
Award Amount: $3,000,000.00
Abstract:
DESCRIPTION (provided by applicant): The development of Sanaria's aseptic, purified, cryopreserved Plasmodium falciparum (Pf) sporozoite (SPZ)-based products has received international recognition during the past year, due principally to four findings: 1)PfSPZ Challenge (infectious PfSPZ)… More

Transgenic Mosquitoes for Improved Malaria Sporozoite Vaccine Manufacture

Award Year / Program / Phase: 2012 / SBIR / Phase II
Agency: HHS
Principal Investigator: Peter F. Billingsley – 301-770-3222
Award Amount: $2,955,385.00
Abstract:
DESCRIPTION (provided by applicant): An ideal tool for eliminating Plasmodium falciparum (Pf), the causative agent of 99% of all malaria deaths, would be a highly effective vaccine that prevents blood stage infection and thereby prevents both disease and transmission. Sanaria's goal is to… More

High Throughput Assay to Identify New Drugs Against Vivax Malaria Liver Stages

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Stephen L. Hoffman – 301-770-3222
Award Amount: $599,998.00
Abstract:
DESCRIPTION (provided by applicant): Plasmodium vivax (Pv) is the 2nd most important human malaria parasite, causing more than 80 million cases annually, and significant severe disease and mortality that were previously unrecognized. Recent data indicate that the impact of Pv malaria on health and… More

Vaccination with purified, cryopreserved, infectious Plasmodium vivax sporozoites

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Stephen L. Hoffman – 301-770-3222
Award Amount: $599,934.00
Abstract:
DESCRIPTION (provided by applicant): Plasmodium vivax (Pv) is the 2nd most important human malaria parasite, causing gt 80 million cases annually. However, efforts to prevent and control Pv malaria face major challenges of drug resistance and repeated relapses from dormant forms. Moreover, Pv… More

Micro_patterned Surfaces for Reducing the Risk of Ventilator_Associated Pneumonia

Award Year / Program / Phase: 2013 / SBIR / Phase I
Agency: HHS
Principal Investigator: Stephen L. Hoffman – 301-770-3222
Award Amount: $599,996.00
Abstract:
DESCRIPTION (provided by applicant): A highly effective vaccine that targets the asymptomatic sporozoite (SPZ) and liver stages of the most lethal human malaria parasite, Plasmodium falciparum (Pf), would be an ideal tool to prevent malaria infection, disease and transmission. After 3 decades of… More

Mentoring Central: Mobile and Web Training for Mentees and their Caregivers

Award Year / Program / Phase: 2013 / SBIR / Phase I
Agency: HHS
Principal Investigator: Stephen L. Hoffman – 301-770-3222
Award Amount: $597,675.00
Abstract:
DESCRIPTION (provided by applicant): The ideal tool for eliminating Plasmodium falciparum (Pf), the causative agent of 99% of all malaria deaths, is a highly effective vaccine that entirely prevents blood stage infection and thereby prevents all disease and transmission. Sanaria's goal is to… More

Plasmodium Falciparum Whole Sporozoite Malaria Vaccine

Award Year / Program / Phase: 2013 / SBIR / Phase II
Agency: HHS
Principal Investigator: Stephen L. Hoffman – 301-770-3222
Award Amount: $2,999,984.00
Abstract:
DESCRIPTION (provided by applicant): The ideal tool for eliminating Plasmodium falciparum (Pf), the causative agent of 99% of all malaria deaths, would be a highly effective vaccine that prevents blood stage infection and thereby prevents the disease and transmission. The only immunogens… More